Straits Times Index
3,384.29 +20.61 (+0.61%) Nikkei
27,509.46 +107.41 (+0.39%) Hang Seng
21,660.47 -297.89 (-1.36%) FTSE 100
7,901.80 +81.64 (+1.04%) BTC-USD
23,347.46 -53.68 (-0.23%) CMC Crypto 200
535.42 -1.43 (-0.27%)
Novartis AG (NVSEF)
- Zacks
Novartis (NVS) Q4 Earnings Top, Revenues Miss Estimates
Novartis (NVS) reports mixed fourth-quarter results, with key brands maintaining momentum but Cosentyx sales declining and generic competition remaining a drag.
- Motley Fool
Novartis Ag (NVS) Q4 2022 Earnings Call Transcript
NVS earnings call for the period ending December 31, 2022.
- Reuters
Novartis says operating profit to grow again ahead of Sandoz spin-off
Novartis on Wednesday predicted that core operating income would grow in a "mid single digit" percentage range in 2023 following stagnation last year, as the Swiss drugmaker prepares to spin off its Sandoz generics business. Full-year core operating income was broadly flat at $16.7 billion, it said in a statement, coming in slightly below market expectations of $16.8 billion. Adjusted for overall negative currency effects, group sales in 2022 advanced 4% to $50.5 billion as gains from heart failure drug Entresto and multiple sclerosis (MS) drug Kesimpta were partly offset by competition from cheap generic copies of established MS drug Gilenya.
